Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorRubio Pérez, Carlota
dc.contributor.authorPlanas Rigol, Ester
dc.contributor.authorTrincado, Juan L.
dc.contributor.authorBonfill Teixidor, Ester
dc.contributor.authorArias Piñeiro, Alexandra
dc.contributor.authorMarchese, Domenica
dc.contributor.authorIurlaro, Raffaella
dc.contributor.authorMartínez Ricarte, Francisco Ramón
dc.contributor.authorEscudero Monreal, Laura
dc.contributor.authorCordero Asanza, Esteban Xavier
dc.contributor.authorCicuendez López Ocaña, Marta
dc.contributor.authorNuciforo, Paolo Giovanni
dc.contributor.authorSahuquillo Barris, Joan
dc.contributor.authorTabernero Caturla, Josep
dc.contributor.authorSeoane Suarez, Joan
dc.contributor.authorSerna, Garazi
dc.date.accessioned2021-07-15T12:22:26Z
dc.date.available2021-07-15T12:22:26Z
dc.date.issued2021-03-08
dc.identifier.citationRubio-Perez C, Planas-Rigol E, Trincado JL, Bonfill-Teixidor E, Arias A, Marchese D, et al. Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment. Nat Commun. 2021 Mar 8;12(1):1503.
dc.identifier.issn2041-1723
dc.identifier.urihttps://hdl.handle.net/11351/6171
dc.descriptionCancer microenvironment; Tumour immunology
dc.description.abstractBrain metastases are the most common tumor of the brain with a dismal prognosis. A fraction of patients with brain metastasis benefit from treatment with immune checkpoint inhibitors (ICI) and the degree and phenotype of the immune cell infiltration has been used to predict response to ICI. However, the anatomical location of brain lesions limits access to tumor material to characterize the immune phenotype. Here, we characterize immune cells present in brain lesions and matched cerebrospinal fluid (CSF) using single-cell RNA sequencing combined with T cell receptor genotyping. Tumor immune infiltration and specifically CD8+ T cell infiltration can be discerned through the analysis of the CSF. Consistently, identical T cell receptor clonotypes are detected in brain lesions and CSF, confirming cell exchange between these compartments. The analysis of immune cells of the CSF can provide a non-invasive alternative to predict the response to ICI, as well as identify the T cell receptor clonotypes present in brain metastasis.
dc.language.isoeng
dc.publisherNature Research
dc.relation.ispartofseriesNature Communications;12(1)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectCervell - Tumors
dc.subjectCàncer - Immunoteràpia
dc.subjectMetàstasi
dc.subject.meshBrain Neoplasms
dc.subject.meshAntineoplastic Agents, Immunological
dc.subject.meshNeoplasm Metastasis
dc.titleImmune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1038/s41467-021-21789-x
dc.subject.decsneoplasias cerebrales
dc.subject.decsinmunoterapia antineoplásica
dc.subject.decsmetástasis neoplásica
dc.relation.publishversionhttps://www.nature.com/articles/s41467-021-21789-x
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Rubio-Perez C, Planas-Rigol E, Bonfill-Teixidor E, Arias A, Serna G, Iurlaro R, Escudero L, Nuciforo P] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Trincado JL] CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain. Josep Carreras Leukemia Research Institute and Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain. [Marchese D] CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain. [Martínez-Ricarte F, Cordero E, Cicuendez M, Sahuquillo J] Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Tabernero J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBERONC, Barcelona, Spain. [Seoane J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBERONC, Barcelona, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
dc.identifier.pmid33686071
dc.identifier.wos000627442600001
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2013-2016/PI16%2F01278
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2013-2016/SAF2017-89109-P
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record